Ultimate Fighting Championship (UFC) light heavyweight bruiser Nick Roehrick found himself in hot water last month after United States Anti-Doping Agency (USADA) notified the once-beaten Floridian of a potential anti-doping violation.
From the official release:
Roehrick, 30, tested positive for clomiphene and its metabolite, 4-hydroxyclomiphene, following an out-of-competition urine test conducted on August 8, 2017. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.
Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) for use in the male population, meaning such off-label clinical use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.
Roehrick’s one-year period of ineligibility, the highest sanction for a first offense involving a Specified Substance, began on August 17, 2017, the date his provisional suspension was imposed.
Roehrick stepped in on short notice to battle Jarod Cannonier at The Ultimate Fighter (TUF) 25 Finale last July in Las Vegas, Nevada. The knockout loss ended a seven-fight win streak and based on this latest news, it could be awhile before Roehrick gets a second shot at his first UFC win.